FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform

Published:2022-02-10 Issue:3 Volume:21 Page:170-170
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Mullard Asher

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.nature.com/articles/d41573-022-00031-3.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances on emerging biosensing technologies and on-site analytical devices for detection of drug-resistant foodborne pathogens;TrAC Trends in Analytical Chemistry;2023-10

2. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy;Frontiers in Oncology;2023-06-22

3. The Interplay between T Cells and Cancer: The Basis of Immunotherapy;Genes;2023-04-28

4. The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy;Cells;2022-12-21

5. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors;International Journal of Molecular Sciences;2022-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP